Filtered By:
Cancer: Breast Cancer
Drug: Xgeva
This page shows you your search results in order of date.
Order by Relevance | Date
Total 90 results found since Jan 2013.
Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis
CONCLUSION: Oncologists may have increased flexibility regarding the frequency of administration of BTT along with their choice of agent. Our study showed no significant difference in the prevention of overall SRE or development of BTT-associated harms between the BTT regimens evaluated.PMID:37735019 | DOI:10.1016/j.clbc.2023.08.008
Source: Clinical Breast Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Athira Jayan Akshara Singareeka Raghavendra Roland Bassett Carlos H Barcenas Source Type: research
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial
CONCLUSIONS: We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.PMID:37725572 | DOI:10.1158/1078-0432.CCR-23-1801
Source: Clinical Genitourinary Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Theresa Link Jens-Uwe Blohmer Wolfgang D Schmitt Jan Dominik Kuhlmann Marianne Just Michael Untch Oliver Stotzer Peter A Fasching Marc Thill Mattea Reinisch Andreas Schneeweiss Pauline Wimberger Sabine Seiler Jens Huober Christian Jackisch Kerstin Rhiem C Source Type: research
Α Humanized RANKL Transgenic Mouse Model of Progestin-Induced Mammary Carcinogenesis for Evaluation of Novel Therapeutics
Cancers (Basel). 2023 Aug 7;15(15):4006. doi: 10.3390/cancers15154006.ABSTRACTReceptor activator of nuclear factor-κB ligand (RANKL) is critically involved in mammary gland pathophysiology, while its pharmaceutical inhibition is being currently investigated in breast cancer. Herein, we investigated whether the overexpression of human RANKL in transgenic mice affects hormone-induced mammary carcinogenesis, and evaluated the efficacy of anti-RANKL treatments, such as OPG-Fc targeting both human and mouse RANKL or Denosumab against human RANKL. We established novel MPA/DMBA-driven mammary carcinogenesis models in TgRANKL mic...
Source: Cancer Control - August 12, 2023 Category: Cancer & Oncology Authors: Anthi Kolokotroni Evi Gkikopoulou Vagelis Rinotas Lydia Ntari Danae Zareifi Maritina Rouchota Sophia Sarpaki Ilias Lymperopoulos Leonidas G Alexopoulos George Loudos Maria C Denis Niki Karagianni Eleni Douni Source Type: research
A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in Chinese Patients With Breast Cancer
CONCLUSION: Denosumab was effective and well tolerated in Chinese breast cancer patients with BM.PMID:37448470 | PMC:PMC10336762 | DOI:10.1177/11795549231182266
Source: Clinical Genitourinary Cancer - July 14, 2023 Category: Cancer & Oncology Authors: Wei Li Xinyu Wu Heng Yu Zekai Zhu Wenjie Li Xiang Huang Source Type: research
The Clinical Benefits of Antiresorptive Agents in Primary Breast Cancer Patients Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis
CONCLUSIONS: Using antiresorptive agents early in breast cancer patients receiving adjuvant endocrine therapy may provide additional benefits in risk reduction of recurrence, but has its potential risk of ONJ.PMID:37170778 | DOI:10.1210/clinem/dgad247
Source: Clinical Breast Cancer - May 12, 2023 Category: Cancer & Oncology Authors: Sheng-Fan Wang Yi-Sheng Lin Wan-Yu Yeh Yuh-Lih Chang Chern-En Chiang Chen-Huan Chen Ling-Ming Tseng Hsin-Chen Lee Chun-Yu Liu Hao-Min Cheng Source Type: research
